C4 Therapeutics, Inc. logo CCCC - C4 Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 10
HOLD 3
SELL 1
STRONG
SELL
0
| PRICE TARGET: $7.00 DETAILS
HIGH: $7.00
LOW: $7.00
MEDIAN: $7.00
CONSENSUS: $7.00
UPSIDE: 96.63%
Metric 2025 2024 2023 2022 2021 2020 2019 2018
Revenue
Revenue 35.9 35.6 20.8 31.1 45.8 33.2 21.4 19.4
Cost of Revenue 8.0 0 7.7 0 0 78.4 0 28.6
Gross Profit 28.0 35.6 13.0 31.1 45.8 (45.2) 21.4 (9.2)
Operating Expenses
R&D Expenses 104.2 110.6 117.7 117.8 94.7 78.4 48.1 28.6
SG&A Expenses 36.2 42.1 42.1 42.8 33.3 15.2 8.8 7.2
Other Expenses (8.0) 2.4 (7.7) 0 0 (78.4) 0 (0.0)
Operating Expenses 132.5 155.2 152.1 160.6 127.9 15.2 56.8 35.8
Operating Income
Operating Income (104.5) (119.6) (139.0) (129.5) (82.1) (60.4) (35.5) (16.4)
Interest Expense 0 0 1.4 2.2 2.1 1.2 0 0
Interest Income 0 14.4 9.8 3.6 0.4 0.4 1.8 0.7
Profitability
EBITDA (102.9) (103.4) (122.1) (124.3) (80.3) (58.8) (31.7) (15.1)
EBIT (104.9) (105.2) (129.8) (126.0) (81.7) (60.4) (33.3) (16.4)
Income Before Tax (104.9) (105.2) (131.2) (128.2) (83.9) (65.7) (33.3) (15.7)
Income Tax Expense 0.1 0.1 1.3 0 0 0.6 0.8 0
Net Income (105.0) (105.3) (132.5) (128.2) (83.9) (66.3) (34.1) (15.7)
Per Share Data
EPS (Basic) -1.27 -1.52 -2.67 -2.62 -1.82 -1.54 -0.79 -1.06
EPS (Diluted) -1.27 -1.52 -2.67 -2.62 -1.82 -1.54 -0.79 -1.06
Shares Outstanding 82.9 69.4 49.6 48.9 46.0 43.1 43.0 14.8
Metric 2025 2024 2023 2022 2021 2020 2019 2018
Current Assets
Cash & Cash Equivalents 74.6 55.5 126.6 29.8 76.1 181.7 90.5 36.3
Short-Term Investments 173.9 189.4 127.1 246.4 233.2 190.0 0 0
Net Receivables 2.4 3.1 11.8 1.5 5.7 4.5 4.6 86.4
Inventory 0 0 0 (61.0) 0 0 0 0
Other Current Assets 7.2 9.8 5.7 70.9 0 0 0 0
Total Current Assets 258.1 257.8 271.2 287.6 325.7 381.0 96.8 123.5
Non-Current Assets
Property, Plant & Equipment 45.3 63.4 71.1 77.5 35.1 16.6 18.9 20.4
Goodwill 0 0 0 0 0 0 0 0
Intangible Assets 0 0 0 0 0 0 0 0
Long-Term Investments 0 22.4 28.0 61.0 142.2 0 0 2.6
Other Non-Current Assets 55.7 6.1 6.2 4.8 3.8 2.6 2.6 0
Total Non-Current Assets 101.0 91.8 105.3 143.3 181.1 19.1 21.5 23.0
Total Assets 359.1 349.6 376.5 430.8 506.8 400.1 118.3 146.5
Current Liabilities
Account Payables 0.9 1.3 1.4 1.2 4.5 5.7 5.4 1.2
Short-Term Debt 6.4 0 0 2.3 0 0 0 0
Deferred Revenue 12.5 18.7 15.5 16.6 31.8 27.6 20.7 19.1
Other Current Liabilities 13.3 9.3 9.4 3.1 5.5 4.2 3.3 1.3
Total Current Liabilities 33.0 45.2 42.8 44.5 51.2 43.9 33.6 23.9
Non-Current Liabilities
Long-Term Debt 0 0 0 9.2 10.8 10.1 0 0
Deferred Tax Liabilities 0 0 0 0 0 0 0 (13.7)
Other Non-Current Liabilities 0 0 0 0 0 0 111.0 111.0
Total Non-Current Liabilities 69.5 88.4 87.6 97.1 65.9 75.5 196.6 202.3
Total Liabilities 102.5 133.6 130.3 141.6 117.2 119.3 230.2 226.2
Stockholders' Equity
Common Stock 0.0 0.0 0.0 0.0 0.0 0.0 0 0.0
Retained Earnings (738.7) (633.7) (528.4) (395.9) (267.7) (183.8) (117.5) (83.4)
Accumulated Other Comprehensive Income 0.1 0.1 (0.1) (4.1) (0.8) 0.0 0 (2.5)
Total Stockholders' Equity 256.6 216.0 246.1 289.2 389.6 280.8 (112.0) (79.8)
Total Liabilities & Equity 359.1 349.6 376.5 430.8 506.8 400.1 118.3 146.5
Debt Metrics
Total Debt 60.0 65.8 71.0 87.2 42.9 22.9 13.7 14.5
Net Debt (14.6) 10.3 (55.6) 57.4 (33.2) (158.8) (76.8) (21.8)
Metric 2025 2024 2023 2022 2021 2020 2019 2018
Operating Activities
Net Income (105.0) (105.3) (132.5) (128.2) (83.9) (66.3) (34.1) (15.7)
Depreciation & Amortization 2.0 1.8 1.9 1.7 1.5 1.6 1.6 1.3
Stock-Based Compensation 19.1 29.7 27.2 30.0 21.5 3.4 1.6 0.6
Change in Working Capital (29.3) 7.6 (6.9) (16.8) (30.1) (13.2) 85.0 (5.6)
Other Non-Cash Items 14.5 1.0 3.5 7.3 2.1 1.6 1.1 2.4
Operating Cash Flow (98.7) (65.2) (106.8) (105.9) (87.0) (67.2) 55.6 (17.0)
Investing Activities
Capital Expenditure (0.6) (0.2) (1.7) (5.5) (1.3) (0.7) (1.3) (2.7)
Acquisitions 0 0 0 (63.9) 188.1 189.9 0.1 0
Purchases of Investments (227.1) (284.3) (129.9) (219.5) (537.7) (293.9) (79) (5.0)
Sales/Maturities of Investments 219.1 233.2 290.0 283.4 349.7 104 78.7 44.6
Other Investing Activities 0 0 0 63.9 (188.1) (189.9) 0 39.6
Investing Cash Flow (8.6) (51.3) 158.3 58.4 (189.3) (190.5) (1.6) 36.9
Financing Activities
Net Debt Issuance 0 0 (12.5) 0 0 12.0 0 0
Stock Repurchased (0.2) (0.2) (0.1) 0 0 (0.2) (0.0) (0.1)
Dividends Paid 0 0 0 0 0 0 0 0
Other Financing Activities 0.3 1.2 0.4 0.4 1.9 (3.4) 0.3 (0.1)
Financing Cash Flow 126.4 45.3 45.5 1.1 171.4 348.9 0.2 2.0
Cash Position
Net Change in Cash 19.1 (71.1) 97 (46.4) (104.9) 91.2 54.2 21.9
Cash at Beginning 58.9 130.0 33.0 79.4 184.3 93.1 38.9 17.0
Cash at End 78.0 58.9 130.0 33.0 79.4 184.3 93.1 38.9
Free Cash Flow (99.3) (65.3) (108.5) (111.4) (88.2) (67.9) 54.3 (19.7)
Key Metrics 2025 2024 2023 2022 2021 2020 2019 2018
Income Statement
Revenue 35.9 35.6 20.8 31.1 45.8 33.2 21.4 19.4
Gross Profit 28.0 35.6 13.0 31.1 45.8 (45.2) 21.4 (9.2)
Operating Income (104.5) (119.6) (139.0) (129.5) (82.1) (60.4) (35.5) (16.4)
Net Income (105.0) (105.3) (132.5) (128.2) (83.9) (66.3) (34.1) (15.7)
EPS (Diluted) -1.27 -1.52 -2.67 -2.62 -1.82 -1.54 -0.79 -1.06
Balance Sheet
Cash & Equivalents 74.6 55.5 126.6 29.8 76.1 181.7 90.5 36.3
Total Assets 359.1 349.6 376.5 430.8 506.8 400.1 118.3 146.5
Total Debt 60.0 65.8 71.0 87.2 42.9 22.9 13.7 14.5
Stockholders' Equity 256.6 216.0 246.1 289.2 389.6 280.8 (112.0) (79.8)
Cash Flow
Operating Cash Flow (98.7) (65.2) (106.8) (105.9) (87.0) (67.2) 55.6 (17.0)
Capital Expenditure (0.6) (0.2) (1.7) (5.5) (1.3) (0.7) (1.3) (2.7)
Free Cash Flow (99.3) (65.3) (108.5) (111.4) (88.2) (67.9) 54.3 (19.7)